Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | BCR | P11274 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16894261 | 0.98 | ABL1 (0.59) | ABL1BCRCYP1A2CYP3A4TRPV1 | |
| SCHEMBL4717327 | 0.82 | ABL1 (0.57) | ABL1BCRTRPV1FAAHKIF11 | |
| SCHEMBL20816287 | 0.81 | CYP1A2 (0.58) | ABL1BCRCYP1A2CYP3A4FAAH | |
| SCHEMBL1014056 | 0.81 | TRPV1 (0.72) | ABL1BCRCYP1A2CYP3A4TRPV1 | |
| Hydrochloric Acid SCHEMBL1012455 | 0.80 | TRPV1 (0.71) | ABL1BCRCYP1A2CYP3A4TRPV1 | |
| SCHEMBL28017373 | 0.80 | ABL1 (0.55) | ABL1BCRCYP1A2CYP3A4JAK2 | |
| SCHEMBL1013728 | 0.80 | ABL1 (0.76) | ABL1BCRCYP1A2CYP3A4TRPV1 | |
| SCHEMBL20816285 | 0.80 | ABL1 (0.55) | ABL1BCRCYP1A2CYP3A4JAK2 | |
| SCHEMBL1012574 | 0.79 | ABL1 (0.75) | ABL1BCRCYP1A2CYP3A4TRPV1 | |
| SCHEMBL28242956 | 0.79 | CYP1A2 (0.58) | CYP1A2CYP3A4FAAHKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105612153-B | Substituted heterocyclic sulfonamide compound as TRPA1 conditioning agents | 豪夫迈·罗氏有限公司 | 2018-09-14 | — | — | CN | disclosed |
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| CN-104684899-B | Substituted sulfonamide compounds | 霍夫曼-拉罗奇有限公司 | 2017-07-04 | — | — | CN | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| CN-106458952-A | Heterocyclic sulfonamide derivative and medicine comprising same | EA制药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| CN-105612153-A | Substituted sulfonamide compounds as TRPA1 conditioner | HOFFMANN LA ROCHE | 2016-05-25 | — | — | CN | disclosed |
| EP-2900642-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| CN-104684899-A | Substituted sulfonamide compounds | HOFFMANN LA ROCHE | 2015-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | TRPA1, TRPV1, TRPV5 | ABL1 1402/4885BCR 1371/4885CYP1A2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.